Literature DB >> 7656789

[Antitumor activities of 8-chloroadenosine in vivo and in vitro].

J Fang1, Y Shi, L Zhang.   

Abstract

8-chloroadenosine showed marked activity against mice solid tumor hepatoma 22 (H22) and ascitic leukemia L-1210. At 100mg. Kg-1. /d x 7, the inhibition rate of H22 was 71.7 +/- 13.3% (P < 0.01) and 66.1 +/- 4.46% (P < 0.01), i.p. and i.v., respectively; at the same dose, the life-prolonging rate of mice bearing L-1210 was 124.0 +/- 22.1% (P < 0.01) and 104.2 +/- 20.1% (P < 0.01), i.p. and i.v., respectively. 8-chloroadenosine also showed activity against 3 human cancer cell lines in vitro. The IC50 values were determined by measuring cell growth using trypan blue dye exclusion. The results showed that HL-60 and K562, and human gastric cancer cell line MGc80-3 and IC50 values of 1. 8 mumol/L, 4.2 mumol/L and 1.56 mumol/L, respectively. The toxicity of 8-chloroadenosine was low, with LD50 of 1025.0 +/- 52.4 mg/kg for mice and 793.4 +/- 70.1 mg/kg for rats by single i.p. injection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7656789

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  3 in total

1.  8-Cl-adenosine-induced inhibition of colorectal cancer growth in vitro and in vivo.

Authors:  C C Carlson; R Chinery; L L Burnham; D T Dransfield
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

2.  8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition.

Authors:  Alper Y Kearney; You-Hong Fan; Uma Giri; Babita Saigal; Varsha Gandhi; John V Heymach; Amado J Zurita
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

3.  Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.

Authors:  Ralf Buettner; Le Xuan Truong Nguyen; Corey Morales; Min-Hsuan Chen; Xiwei Wu; Lisa S Chen; Dinh Hoa Hoang; Servando Hernandez Vargas; Vinod Pullarkat; Varsha Gandhi; Guido Marcucci; Steven T Rosen
Journal:  J Hematol Oncol       Date:  2021-04-26       Impact factor: 17.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.